Clinical Trial Update: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating LNK01001 Capsule for adults with moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• LNK01001 Capsule

Snippet

Sponsor: Lynk Pharmaceuticals Co., Ltd | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED